▟ Vinebot intrinsic value, daily

← back

ILMN Illumina, Inc.

pharma · valued with glm-5.2 medium conviction · deep-dived 2026-09-22

SELL
Intrinsic value$60.73
Price (at call)$238.82
Margin of safety -74.6%
vs market (rating basis) -36.1%

Model unavailable; showing baseline valuation.

⚠ LLM error: empty response; using baseline

The story

Value drivers

Revenue growth (Y1)-1.8%
Terminal growth3.5%
Forecast horizon10y
Target operating margin26.4%
Years to target margin5
Sales-to-capital0.93
Beta1.47
Failure probability0.0%
Cost of capital (WACC)11.2%
Terminal WACC9.2%

Valuation bridge

PV of explicit FCFF5.00B
PV of terminal value4.74B
Equity value9.17B
÷ shares → per share$60.73

News

neutral +0.10 · 8 articles

  • Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further.
  • 1 Surging Stock to Target This Week and 2 We Question
  • Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?
  • US Stock Market Today: S&P 500 Futures Edge Higher As Bond Yield Jitters Linger
  • Intel Upgraded, CVS Health Downgraded: Updated Rankings on Top Blue-Chip Stocks
  • S&P Dow Jones Indices CEO on Index Restructuring
  • Dear Illumina Stock Fans, Mark Your Calendars for September 21
  • Dear Everpure Stock Fans, Mark Your Calendars for September 21

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 4.31B -1.8% 26.4% 891.72M 0 891.72M 801.73M
2 4.26B -1.2% 26.4% 881.05M 0 881.05M 712.19M
3 4.24B -0.6% 26.4% 875.67M 0 875.67M 636.42M
4 4.24B -0.0% 26.4% 875.47M 0 875.47M 572.06M
5 4.26B 0.6% 26.4% 880.42M 25.64M 854.77M 502.17M
6 4.31B 1.2% 26.4% 890.55M 52.62M 837.94M 442.60M
7 4.38B 1.7% 26.4% 906.04M 80.36M 825.68M 392.11M
8 4.49B 2.3% 26.4% 927.11M 109.36M 817.75M 349.15M
9 4.62B 2.9% 26.4% 954.11M 140.16M 813.96M 312.46M
10 4.78B 3.5% 26.4% 987.51M 173.31M 814.20M 281.01M